Scholarlink

Purpose <p>To analyze the association between myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) and PARP inhibitors (PARPi), to explore predisposing factors, and to evaluate their effectiveness and safety in clinical practice.</p> Methods <p>Observational, analytical and retrospective study including patients with ovarian cancer treated with olaparib or niraparib from 2014 to 2024. Primary endpoint was to identify the incidence and risk factors of secondary malignancy, considering treatment duration, BRCA mutation, lines of platinum-based chemotherapy and grade 3–4 adverse events (AEs). Overall survival (OS), progression-free survival (PFS), and AEs were recorded.</p> Results <p>Eighty patients were included. Six developed secondary MDS/AML, with an incidence of 11.6% (5/43) for olaparib and 2.7% (1/37) for niraparib. No significant correlation was found, except for hematological grade 3–4 AEs, associated with a higher risk of developing MDS/AML (OR: 32.3 <i>p</i> = 0.001). The median latency period was 8.8&#xa0;months (1.5–102.2). For olaparib, median PFS was 37.8&#xa0;months (95% CI 17.0–58.6); OS was not reached. For niraparib PFS was 10.0&#xa0;months (95% CI 7.4–12.5), OS 25.1&#xa0;months (95% CI 6.3–43.9). Grade 3–4 AEs occurred in 32.6% of olaparib and 35.2% of niraparib patients, mainly anemia and thrombocytopenia.</p> Conclusions <p>PARPi are effective and generally with a manageable safety profile. However, secondary MDS and AML, though rare, remain serious adverse events with incompletely defined risk factors. The observed incidence, particularly with olaparib, is comparable to or higher than that reported in trials, though the sample size was limited. Close monitoring of hematologic AEs may be key to preventing these neoplasms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world incidence and risk of myelodysplastic syndrome and acute myeloid leukemia secondary to PARP inhibitors in ovarian cancer

  • 期刊论文

  • 发表日期：

    2025年12月6日

查看全文
  • Javier Corazón Villanueva,
  • Cristina González Pérez,
  • Ainhoa Arenaza Peña,
  • Gloria Marquina,
  • Antonio Casado Herraez,
  • Rafael Sánchez-del Hoyo

摘要

Purpose

To analyze the association between myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) and PARP inhibitors (PARPi), to explore predisposing factors, and to evaluate their effectiveness and safety in clinical practice.

Methods

Observational, analytical and retrospective study including patients with ovarian cancer treated with olaparib or niraparib from 2014 to 2024. Primary endpoint was to identify the incidence and risk factors of secondary malignancy, considering treatment duration, BRCA mutation, lines of platinum-based chemotherapy and grade 3–4 adverse events (AEs). Overall survival (OS), progression-free survival (PFS), and AEs were recorded.

Results

Eighty patients were included. Six developed secondary MDS/AML, with an incidence of 11.6% (5/43) for olaparib and 2.7% (1/37) for niraparib. No significant correlation was found, except for hematological grade 3–4 AEs, associated with a higher risk of developing MDS/AML (OR: 32.3 p = 0.001). The median latency period was 8.8 months (1.5–102.2). For olaparib, median PFS was 37.8 months (95% CI 17.0–58.6); OS was not reached. For niraparib PFS was 10.0 months (95% CI 7.4–12.5), OS 25.1 months (95% CI 6.3–43.9). Grade 3–4 AEs occurred in 32.6% of olaparib and 35.2% of niraparib patients, mainly anemia and thrombocytopenia.

Conclusions

PARPi are effective and generally with a manageable safety profile. However, secondary MDS and AML, though rare, remain serious adverse events with incompletely defined risk factors. The observed incidence, particularly with olaparib, is comparable to or higher than that reported in trials, though the sample size was limited. Close monitoring of hematologic AEs may be key to preventing these neoplasms.